Former MLB star Chet Lemon to throw out first pitch at UCF-UF game
The former Major League Baseball star spent 16 seasons with the Chicago White Sox and Detroit Tigers before coaching in ...
verywellhealth1d
Types and Causes of Blood Clotting Disorders
Blood clotting disorders can be inherited or acquired. Some types cause excessive bleeding, while others cause excessive ...
The Pharma Letter1d
Positive Phase III VERIFY results of rusfertide in PV
US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the ...
Agios to Present at Upcoming Investor Conferences
The live webcast for each event will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. Replays of the webcasts will be archived on ...
Protagonist Therapeutics price target raised to $57 from $53 at JPMorgan
JPMorgan raised the firm’s price target on Protagonist Therapeutics (PTGX) to $57 from $53 and keeps an Overweight rating on the shares. The ...
Monthly Prescribing Reference1d
Rusfertide Improves Hematocrit Control in Patients With Polycythemia Vera
Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...
Protagonist And Takeda Announce Positive Topline Results From Phase 3 VERIFY Study Of Rusfertide In Patients With Polycy...
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...
BioPharma Dive2d
Protagonist says Takeda-partnered drug succeeds in rare blood cancer
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...
Cure Today2d
Rusfertide Elicits Promising Responses in Polycythemia Vera
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...
STAT2d
Protagonist drug hits goals in pivotal study of rare blood cancer
An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...
Targeted Oncology2d
Rusfertide Shows Superior Efficacy in Phase 3 Polycythemia Vera Trial
Rusfertide outperformed placebo in polycythemia vera, meeting all primary and secondary end points in the phase 3 VERIFY ...